- 全部删除
- 您的购物车当前为空
Sirtratumab Vedotin (ASG-15ME) 是一种抗体-药物偶联物(ADC),由靶向SLITRK6的单克隆抗体与强效细胞毒剂单甲基奥瑞他汀E(MMAE)共价连接而成。Sirtratumab Vedotin旨在将破坏微管的有效载荷MMAE选择性递送至表达SLITRK6抗原的肿瘤细胞,使其在膀胱癌和转移性尿路上皮癌研究中具有重要潜力。
Sirtratumab Vedotin (ASG-15ME) 是一种抗体-药物偶联物(ADC),由靶向SLITRK6的单克隆抗体与强效细胞毒剂单甲基奥瑞他汀E(MMAE)共价连接而成。Sirtratumab Vedotin旨在将破坏微管的有效载荷MMAE选择性递送至表达SLITRK6抗原的肿瘤细胞,使其在膀胱癌和转移性尿路上皮癌研究中具有重要潜力。
产品描述 | Sirtratumab Vedotin (ASG-15ME) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody that targets SLITRK6 covalently linked to the potent cytotoxic agent monomethyl auristatin E (MMAE). Sirtratumab Vedotin is designed to selectively deliver the microtubule-disrupting payload MMAE to tumor cells expressing the SLITRK6 antigen, granting it significant potential for research in bladder cancer and metastatic urothelial carcinoma. |
别名 | 斯妥尤单抗, Ha15-10ac12.1, Ha15-10ac12, AGS15C |
CAS No. | 1824663-82-2 |
存储 | store at low temperature | store at -80°C | Shipping with blue ice/Shipping at ambient temperature. |
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容